Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Summary as of May 17, 2018

May 17, 2018 - By Elizabeth Bryant

During Q4 2017 the big money sentiment decreased to 0.98. That’s change of 0.31, from 2017Q3’s 1.29. 20 investors sold all, 70 reduced holdings as Integra LifeSciences Holdings Corporation ratio worsened. 65 increased positions while 23 funds bought positions. Funds hold 70.22 million shares thus 2.95% more from 2017Q3’s 68.21 million shares.
Johnson Gp holds 1,797 shs or 0.01% of its capital. Great Lakes Advisors Llc holds 0.21% or 199,665 shs. Stone Ridge Asset Limited Liability Company owns 7,526 shs. Westfield Cap Mgmt Company Lp accumulated 0.44% or 1.22 million shs. Price T Rowe Assoc Md owns 26,161 shs. Renaissance Ltd Com has 0.02% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 405,800 shs. Pub Employees Retirement Association Of Colorado invested in 12,648 shs. Texas Permanent School Fund invested in 0.03% or 42,969 shs. First Advsrs Lp holds 18,879 shs or 0% of its capital. Panagora Asset Management Incorporated reported 2,030 shs stake. Vanguard Group reported 5.90M shs or 0.01% of all its holdings. Credit Suisse Ag reported 87,254 shs stake. Moreover, Rafferty Asset Mngmt Ltd has 0.01% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 16,627 shs. Envestnet Asset Mgmt invested 0% of its capital in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Piedmont Inv Ltd Liability Corp holds 13,065 shs.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Total analysts of 9 have positions in Integra Lifesciences (NASDAQ:IART) as follows: 3 rated it a “Buy”, 0 with “Sell” and 6 with “Hold”. The positive are 33%. Since January 2, 2018 according to StockzIntelligence Inc Integra Lifesciences has 10 analyst reports. On Thursday, April 26 the stock has “Neutral” rating by JP Morgan. On Tuesday, January 2 the firm has “Market Perform” rating by Raymond James given. On Thursday, March 29 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Buy” rating given by Oppenheimer. On Wednesday, February 28 the firm earned “Market Outperform” rating by JMP Securities. On Wednesday, April 25 the stock has “Hold” rating by Cantor Fitzgerald. The company rating was downgraded by Bank of America on Tuesday, January 2. On Wednesday, April 25 the firm has “Buy” rating given by Jefferies. On Wednesday, April 11 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Neutral” rating given by JP Morgan. Listed here are Integra LifeSciences Holdings Corporation (NASDAQ:IART) PTs and latest ratings.

25/04/2018 Broker: Jefferies Rating: Buy New Target: $70.0000 Maintain
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $55 New Target: $57 Maintain
25/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $52.0000 Maintain
11/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $50 New Target: $55 Maintain
05/04/2018 Broker: BTIG Research Rating: Neutral New Target: $56 Initiates Coverage On
29/03/2018 Broker: Oppenheimer Rating: Buy New Target: $58.0000 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $57 New Target: $60 Maintain
08/01/2018 Broker: Barclays Capital Rating: Hold New Target: $53.0
02/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $55 Downgrade
02/01/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade

The stock increased 1.04% or $0.66 during the last trading session, touching $63.85.Integra LifeSciences Holdings Corporation is uptrending after having risen 29.35% since May 17, 2017. IART has 666,578 volume or 5.58% up from normal. IART outperformed by 17.80% the S&P 500.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The company has $5.23 billion market cap. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.77.87 is the P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

A couple more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were released by: Globenewswire.com which released on May 17, 2018 “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …”, also Globenewswire.com on May 09, 2018 released “Integra LifeSciences Announces Proposed Public Offering of Common Stock”, the next Globenewswire.com is “Integra LifeSciences Prices Public Offering of Common Stock” on May 09, 2018. Globenewswire.com has article titled “Integra LifeSciences Reports First Quarter 2018 Financial Results”.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.